• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Kemin Pharma BVBA - Product Pipeline Review - Q4 2010 Product Image

Kemin Pharma BVBA - Product Pipeline Review - Q4 2010

  • ID: 1446413
  • November 2010
  • 36 pages
  • GlobalData

Kemin Pharma BVBA – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Kemin Pharma BVBA - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Kemin Pharma BVBA - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Kemin Pharma BVBA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Kemin Pharma BVBA Snapshot
Kemin Pharma BVBA Overview
Key Information
Key Facts
Kemin Pharma BVBA – Research and Development Overview
Key Therapeutic Areas
Kemin Pharma BVBA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Kemin Pharma BVBA – Pipeline Products Glance
Kemin Pharma BVBA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Kemin Pharma BVBA–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Kemin Pharma BVBA – Drug Profiles
ANAEBAN
Product Description
Mechanism of Action
R&D Progress
Inflammaban
Product Description
Mechanism of Action
R&D Progress
KPE02004
Product Description
Mechanism of Action
R&D Progress
KPE06001
Product Description
Mechanism of Action
R&D Progress
KPE00001116
Product Description
Mechanism of Action
R&D Progress
KPE00000297
Product Description
Mechanism of Action
R&D Progress
KPE00000313
Product Description
Mechanism of Action
R&D Progress
KPE00001113
Product Description
Mechanism of Action
R&D Progress
KPE00001175
Product Description
Mechanism of Action
R&D Progress
KPE03003015
Product Description
Mechanism of Action
R&D Progress
KPE03003017
Product Description
Mechanism of Action
R&D Progress
KPE03003028
Product Description
Mechanism of Action
R&D Progress
KPE05001
Product Description
Mechanism of Action
R&D Progress
Kemin Pharma BVBA – Pipeline Analysis
Kemin Pharma BVBA – Pipeline Products by Therapeutic Class
Kemin Pharma BVBA Pipeline Products By Target
Kemin Pharma BVBA – Pipeline Products by Molecule Type
Kemin Pharma BVBA - Dormant Projects
Kemin Pharma BVBA – Locations And Subsidiaries
Head Office
Recent Developments
Feb 09, 2004: Company Announces Development Of Two New Molecules To Battle Virus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS